-
Microtubule and Mitosis review(Post)
Introduction Microtubules are key components of the cytoskeleton and are composed of alpha and beta tubulin. These dimerise in a head to tail fashion to form 13 linear protofilaments.
Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Targeting IL-10R: Enhancing Immune Activation in Cancer(Post)Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma
cGAS-STING cytosolic DNA sensing(Page) Cancer Research Club March 2020(Post)ELISA Genie is delighted to announce the date of our next Cancer Research Club which will be taking place on the 31st of March at TTMI, Trinity College Dublin. This event will focu
Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
Citrullination, NETs and Rheumatoid Arthritis(Page) Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Preeclampsia & immune cell regulation | Assay Genie(Post)What is preeclampsia? According to the World Health Organization (WHO), one in ten pregnant women is affected by hypertensive disorders, and preeclampsia a
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research(Post)Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
Growth Factors Can Cooperate to Promote Tumorigenesis(Post)Introduction Tumorigenesis, the process by which normal cells transform into cancer cells, is a multifaceted and complex event influenced by various internal and external factors. Among the
Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying
Agarose vs Polyacrylamide: A Comparative Analysis(Post)Techniques · Gel ElectrophoresisAgarose vs Polyacrylamide: A Comparative AnalysisAgarose and polyacrylamide are the two workhorse gel matrices of electrophoresis. Agarose gels resolve larger DNA and R
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap
PharmaGenie ELISA キット(Page)PharmaGenie ELISA キット | Assay Genie | Assay Genie
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Early Diagnosis is key: Pick the weed or allow it destroy the garden?(Post)By Catríona Dowling, Post-Doc, RCSI I want you to come on a journey with me where we are going to the botanic gardens. You will pick a section of the garden that is yours: yours to treasure